Product image of Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous) supplied by GNH India

Mywy

Active Ingredient:
Drospirenone, Ethinylestradiol | Lactose Anhydrous
Origin:
EU

Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone/Ethinylestradiol, the active ingredients in Mywy, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy by suppressing ovulation and altering cervical mucus in women of reproductive age.

GNH India supplies Mywy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mywy, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

  • Prevention of pregnancy: provides reliable contraception for women of childbearing potential.
  • Regulation of menstrual cycles: helps achieve more predictable bleeding patterns.
  • Treatment of moderate acne: reduces androgen‑driven skin lesions in eligible patients.

How It Works

  • Drospirenone acts as a progestogenic agent with anti‑mineralocorticoid and anti‑androgenic activity, while ethinylestradiol provides estrogenic stimulation. Together they suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation, and they also thicken cervical mucus and alter endometrial development to inhibit implantation.

Side Effects

Mywy may cause a range of adverse reactions. Most are mild and transient.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: discomfort or swelling of the breasts.
  • Headache: occasional throbbing pain.
  • Spotting or breakthrough bleeding: irregular light bleeding.
  • Weight gain: modest increase in body weight.
  • Mood changes: irritability or mood swings.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Arterial thrombosis: stroke or myocardial infarction.
  • Hypertension: new‑onset or worsening high blood pressure.
  • Liver disorders: cholestatic jaundice or hepatic dysfunction.
  • Gallbladder disease: gallstones or cholecystitis.
  • Severe allergic reaction: anaphylaxis or angioedema.

Precautions & Warnings

Before prescribing Mywy, clinicians should evaluate individual risk factors and counsel patients on safe use.

  • Assess cardiovascular risk: review history of thrombosis, smoking, and hypertension.
  • Screen for liver disease: avoid use in active hepatic impairment.
  • Evaluate migraine history: contraindicated in migraine with aura.
  • Counsel on smoking: advise cessation, especially in women >35 years.
  • Review medication list: consider potential drug interactions.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Avoid Interactions

Mywy can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy.
  • Other estrogen‑containing products (e.g., hormone therapy): increase overall estrogen exposure and risk of thromboembolism.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole, itraconazole): may increase plasma levels of ethinylestradiol.
  • Macrolide antibiotics (e.g., erythromycin, clarithromycin): can modestly raise estrogen concentrations.
  • Antidepressants (e.g., SSRIs): may increase risk of mood‑related side effects.

Frequently Asked Questions

Mywy is a combined oral contraceptive containing drospirenone and ethinylestradiol. It is primarily prescribed to prevent pregnancy in women of reproductive age. In addition, it may be used to regulate menstrual cycles and to treat moderate acne when clinically appropriate.

Drospirenone provides progestogenic activity with anti‑mineralocorticoid and anti‑androgenic effects, while ethinylestradiol supplies estrogenic stimulation. Together they suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation, and they also thicken cervical mucus and modify the endometrium to reduce the chance of implantation.

The dosing schedule for Mywy is determined by the prescribing healthcare professional. Typically, it involves a 21‑day series of active tablets followed by a 7‑day placebo or hormone‑free interval, but the exact regimen should be confirmed with the prescriber.

Mywy is not intended for use during pregnancy and should be discontinued if pregnancy occurs. Limited data exist for breastfeeding; the product is generally not recommended unless the benefits to the mother outweigh potential risks to the infant.

To order Mywy, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mywy contains the same drospirenone/ethinylestradiol combination found in many branded products such as Yasmin. Its efficacy, safety profile and hormonal balance are comparable, while formulation differences (e.g., tablet size, inactive ingredients) may affect tolerability for individual patients.

Mywy tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Mywy is taken orally, once daily, preferably at the same time each day. Tablets may be swallowed with or without food. A new pack is started after the placebo interval or as directed by the prescriber.

The most serious risks include venous thromboembolism, arterial thrombosis (stroke or myocardial infarction), severe hypertension, and rare liver or gallbladder disorders. Patients should seek immediate medical attention if they experience unexplained leg pain, chest pain, severe headache, or visual changes.

Mywy is contraindicated in women with a history of thromboembolic disorders, estrogen‑dependent tumors, active liver disease, uncontrolled hypertension, known or suspected pregnancy, or those who smoke heavily and are over 35 years old. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol | Lactose Anhydrous

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT